Medpace Holdings Inc ( (MEDP) ) has released its Q4 earnings. Here is a breakdown of the information Medpace Holdings Inc presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Medpace Holdings, Inc. is a global clinical contract research organization that offers Phase I-IV clinical development services to the biotechnology, pharmaceutical, and medical device industries, specializing in various therapeutic areas such as oncology and cardiology.
In its latest earnings report, Medpace Holdings, Inc. announced a revenue increase of 7.7% for the fourth quarter of 2024, reaching $536.6 million compared to the same period in the previous year. The company also reported a significant rise in GAAP net income, which more than doubled to $117.0 million.
Key highlights from the report include an increase in EBITDA by 39.3% to $133.5 million and a notable improvement in net income margin from 15.7% to 21.8%. Despite a decrease in net new business awards, the company maintained a healthy backlog conversion rate and expanded its share repurchase program by $600 million.
Looking ahead, Medpace’s management forecasts modest revenue growth for 2025, with expectations of revenue ranging between $2.110 billion to $2.210 billion. The company aims to leverage its strong financial position and strategic initiatives to sustain its growth trajectory in the competitive CRO market.
